Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
COPENHAGEN, Denmark, July 14, 2017 -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that the upgrade of its production facility was completed this week. The upgrade has been in process the last 6 weeks and has included an additional storage container, improved mixing machines and upscale filtration unit. The upgrade allows Vilact Bio Inc to increase its production of its Lactoactive® molecule and output with an estimated 300% which the company anticipates will be needed as a part of the new range of products that is being launched this fall.
“This is another important step in our evolution as a skin care and Biotech Company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Find out about Vilact on instagram https://www.instagram.com/vilact_com/ and facebook https://da-dk.facebook.com/skincare.vilact/.
Vilacto Bio Inc. The Seagram Building 375 Park Avenue, Suite 2607 New York City, NY 10152 Gert Andersen Phone: +1 646-893-7895 [email protected] www.vilactobio.com Source: Vilacto Bio Inc.
